 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...1011121314151617181920...235236» |
- |||||| Vectibix (panitumumab) / Amgen, Lumakras (sotorasib) / Amgen, Mvasi (bevacizumab-awwb) / Daiichi Sankyo, Amgen, AbbVie
Enrollment open: CodeBreaK 301: Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-na (clinicaltrials.gov) - Jul 31, 2024
P3, N=450, Recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting
- |||| Yidafan (ivonescimab) / Akesobio, Summit Therapeutics
New P2 trial, Metastases: SEVILLA: Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients (clinicaltrials.gov) - Jul 30, 2024
P2, N=72, Not yet recruiting, Sponsor: UNICANCER
- | 5-fluorouracil / Generic mfg.
Journal, Checkpoint inhibition, Metastases: Efficacy and safety of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk. (Pubmed Central) - Jul 30, 2024
FOLFOX-based HAIC combined with TKIs and ICIs induced an objective response rate of 75.68% in PVTT. FOLFOX-based HAIC combined with TKIs and ICIs provides more treatment options for PVTT.
- TRANSIENT PHENYLKETONURIA IN NEWBORN SCREENING PROGRAM DUE TO CONGENITAL TOXOPLASMOSIS TREATMENT (Poster Room | Level 0) - Jul 30, 2024 - Abstract #SSIEM2024SSIEM_986;
Pyrimethamine hampers folic acid synthesis by inhibiting dihydrofolate reductase (DHFR), a key enzyme in tetrahydrobiopterin synthesis, possibly explaining alterations in both phenylalanine and biopterin. Palavras-chave : Phenylketonuria, Toxoplasmosis, Newborn screening
- leucovorin calcium / Generic mfg.
CEREBRAL FOLATE DEFICIENCY DUE TO FOLATE RECEPTOR ?-DEFECT: A CASE FROM TURKEY (Poster Room | Level 0) - Jul 30, 2024 - Abstract #SSIEM2024SSIEM_908;
We report this case to highlight the importance of genetic testing for diagnosis of treatable refractory seizures of infancy to optimize clinical outcomes. Palavras-chave : Cerebral folate deficiency, FOLR1 gene, Folinic acid, Developmental regression
- Kineret (anakinra) / SOBI, Rituxan (rituximab) / Roche
EXPANDING THE PHENOTYPE OF METHYLENE TETRAHYDROFOLATE DEHYDROGENASE 1 DEFICIENCY (MTHFD1) (Poster Room | Level 0) - Jul 30, 2024 - Abstract #SSIEM2024SSIEM_398;
Inflammation and dysregulation of the immune response have not previously been associated with MTHFD1 deficiency. Given the number of cases reported in the literature, it is likely that we have yet to elucidate the full clinical spectrum of this disorder.
- leucovorin calcium / Generic mfg., hydroxocobalamin (vit B12) / Generic mfg.
PRESENTATION, DIAGNOSIS AND OUTCOME OF METHIONINE SYNTHASE DEFICIENCY IN NORWAY (Poster Room | Level 0) - Jul 30, 2024 - Abstract #SSIEM2024SSIEM_381;
However, due to delay of exact diagnosis and lack of treatment guidelines at that time period, therapy was fragmented and inconsistent. Pending the development of more efficient treatment, detection by newborn screening may improve outcome.
- || Ampligen (rintatolimod) / AIM ImmunoTech
Trial completion date, Trial primary completion date: Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC (clinicaltrials.gov) - Jul 30, 2024
P2, N=90, Recruiting, Sponsor: AIM ImmunoTech Inc.
Pending the development of more efficient treatment, detection by newborn screening may improve outcome. Trial completion date: Jul 2027 --> Apr 2028 | Trial primary completion date: Jun 2027 --> Mar 2028
- | irinotecan / Generic mfg.
Trial completion, Trial completion date: XCHT for Irinotecan-Induced Gut Toxicities (Run-in Study) (clinicaltrials.gov) - Jul 30, 2024
P=N/A, N=24, Completed, Sponsor: Guangzhou University of Traditional Chinese Medicine
Trial completion date: Jul 2027 --> Apr 2028 | Trial primary completion date: Jun 2027 --> Mar 2028 Recruiting --> Completed | Trial completion date: Oct 2024 --> Jul 2024
- | Elzonris (tagraxofusp-erzs) / Menarini
Enrollment closed, Enrollment change: Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Jul 29, 2024
P1/2, N=4, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed | Trial completion date: Oct 2024 --> Jul 2024 Recruiting --> Active, not recruiting | N=40 --> 4
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Journal, Tumor mutational burden, PD(L)-1 Biomarker, Metastases: Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study. (Pubmed Central) - Jul 29, 2024
First-line FOLFOXIRI/bevacizumab plus atezolizumab improves OS in patients with mCRC. In the pMMR group, patients with Immunoscore IC-high and/or TMB-high tumors are identified as a subgroup of interest to further develop this treatment.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Journal, Combination therapy, Metastases: BRAF K601E-mutated metastatic colorectal cancer in response to combination therapy with encorafenib, binimetinib, and cetuximab: A case report. (Pubmed Central) - Jul 29, 2024
In the pMMR group, patients with Immunoscore IC-high and/or TMB-high tumors are identified as a subgroup of interest to further develop this treatment. This case offers novel insights into the clinical behaviors of BRAF non-V600E-mCRC, potentially advancing personalized therapy for rare and aggressive cases.
- | Lonsurf (trifluridine/tipiracil) / Otsuka, Opdivo (nivolumab) / BMS
Journal, Metastases: Trifluridine/tipiracil + oxaliplatin (Pubmed Central) - Jul 28, 2024
P2
This case offers novel insights into the clinical behaviors of BRAF non-V600E-mCRC, potentially advancing personalized therapy for rare and aggressive cases. PRODIGE73-UCGI40-LOGICAN study will provide efficacy and safety data on the association of FTD/TPI plus oxaliplatin with or without nivolumab versus FOLFOX regimen with or without nivolumab in first-line palliative setting, in patients with aGA/GEJA (NCT05476796).
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: Pathological complete response with FOLFIRINOX therapy for recurrence of pancreatic acinar cell carcinoma. (Pubmed Central) - Jul 28, 2024
PRODIGE73-UCGI40-LOGICAN study will provide efficacy and safety data on the association of FTD/TPI plus oxaliplatin with or without nivolumab versus FOLFOX regimen with or without nivolumab in first-line palliative setting, in patients with aGA/GEJA (NCT05476796). He received eight cycles of irinotecan plus cisplatin chemotherapy...The patient has remained well with no recurrence for 6
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Metastases: Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients. (Pubmed Central) - Jul 28, 2024
FOLFIRINOX+cetuximab provides good PFS, high response rate and prolonged disease control in initially unresectable extended RAS wild-type mCRC. This combination is particularly interesting for selected patients with liver-limited disease eligible to secondary resection.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: Safety and Feasibility of Neoadjuvant-Modified FOLFIRINOX in Elderly Patients with Pancreatic Cancer. (Pubmed Central) - Jul 27, 2024
The perioperative and postoperative outcomes of elderly patients treated with neoadjuvant mFOLFIRINOX were comparable with those of non-elderly patients. Neoadjuvant mFOLFIRINOX should be considered a feasible option for elderly patients with PC.
- || Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Clinical, Retrospective data, Journal, Metastases: Safety of first-line systemic therapy in patients with metastatic colorectal cancer: a network meta-analysis of randomized controlled trials. (Pubmed Central) - Jul 26, 2024
Neoadjuvant mFOLFIRINOX should be considered a feasible option for elderly patients with PC. In summary, the CAPOX regimen may be the safest option among the first-line systemic treatment regimens for mCRC patients, while the FOLFOXIRI?+?panitumumab regimen may be associated with a higher incidence of grade 3 or higher AEs.
- | oleclumab (MEDI9447) / AstraZeneca, Avastin (bevacizumab) / Roche, Imfinzi (durvalumab) / AstraZeneca
Journal, Combination therapy, Metastases: COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer. (Pubmed Central) - Jul 26, 2024
P1/2
In summary, the CAPOX regimen may be the safest option among the first-line systemic treatment regimens for mCRC patients, while the FOLFOXIRI?+?panitumumab regimen may be associated with a higher incidence of grade 3 or higher AEs. The safety profile of FOLFOX and bevacizumab in combination with durvalumab and oleclumab was manageable; however, the efficacy results do not warrant further development of this combination in patients with microsatellite stable mCRC.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal, Metastases: Use of trastuzumab and pertuzumab with FOLFOXIRI as neoadjuvant therapy for HER2-positive resectable metastatic colorectal cancer: The first case report. (Pubmed Central) - Jul 26, 2024
The safety profile of FOLFOX and bevacizumab in combination with durvalumab and oleclumab was manageable; however, the efficacy results do not warrant further development of this combination in patients with microsatellite stable mCRC. No abstract available
- || Lumakras (sotorasib) / Amgen
Trial primary completion date, Monotherapy: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Jul 25, 2024
P1, N=1200, Recruiting, Sponsor: Amgen
No abstract available Trial primary completion date: Dec 2026 --> Sep 2025
- | faecalibacterium prausnitzii EXL01-strain (EXL01) / Exeliom Biosciences, Opdivo (nivolumab) / BMS
Enrollment open, Trial initiation date: BIG: First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ?5 Metastatic Gastric Cancer (clinicaltrials.gov) - Jul 25, 2024
P2, N=120, Recruiting, Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
Trial primary completion date: Dec 2026 --> Sep 2025 Not yet recruiting --> Recruiting | Initiation date: Mar 2024 --> Jul 2024
- | Trial primary completion date, Metastases: ShorTrip: Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29 (clinicaltrials.gov) - Jul 24, 2024
P2, N=63, Active, not recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
Not yet recruiting --> Recruiting | Initiation date: Mar 2024 --> Jul 2024 Trial primary completion date: May 2024 --> Dec 2024
- || Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
New P2 trial, Combination therapy, Metastases: Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jul 23, 2024
P2, N=20, Not yet recruiting, Sponsor: Cornerstone Pharmaceuticals
- | leucovorin calcium / Generic mfg.
Journal, Metastases: NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype? (Pubmed Central) - Jul 23, 2024
Trial primary completion date: May 2024 --> Dec 2024 No abstract available
- | Imkeldi (imatinib) / Shorla Oncology
Enrollment closed, IO biomarker: AALL1631: Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 23, 2024
P3, N=475, Active, not recruiting, Sponsor: Children's Oncology Group
No abstract available Recruiting --> Active, not recruiting
- ||| Natrunix (vilamakitug) / XBiotech
Trial completion, Trial primary completion date: 1-BETTER: XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer (clinicaltrials.gov) - Jul 23, 2024
P1/2, N=76, Completed, Sponsor: XBiotech, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Feb 2024 --> Oct 2023
- | magrolimab (ONO-7913) / Ono Pharma
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy, Metastases: ELEVATE CRC: Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Jul 22, 2024
P2, N=77, Terminated, Sponsor: Gilead Sciences
Active, not recruiting --> Completed | Trial primary completion date: Feb 2024 --> Oct 2023 N=135 --> 77 | Trial completion date: Nov 2026 --> Jun 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2025 --> Jun 2024; Sponsor decision to terminate study
- || irinotecan hydrochloride liposome injection (HR070803) / Jiangsu Hengrui Pharma, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
P1 data, Journal, Combination therapy, Metastases: Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion study. (Pubmed Central) - Jul 22, 2024
P1
Retrospectively registered on Oct. 12, 2021.
- | Journal, Metastases: Clinical Analysis of the Efficacy and Safety of Different Neoadjuvant Strategies in the Treatment of Locally Advanced Rectal Cancer. (Pubmed Central) - Jul 22, 2024
The RT?+?XELOX group also reduced the 3-year distant metastasis rate, increased the 3-year overall survival rate, and did not increase the incidence of perioperative surgical complications. It provides an effective means for the comprehensive treatment of locally advanced rectal cancer and has important clinical guidance and application value.
- | Vectibix (panitumumab) / Amgen
New P3 trial: IMPROVE-2: Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 22, 2024
P3, N=500, Recruiting, Sponsor: National Cancer Institute, Naples
- || 5-fluorouracil / Generic mfg., sorafenib / Generic mfg.
Clinical, Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases: Cost-Effectiveness Analysis of Hepatic Arterial Chemotherapy for Advanced Hepatocellular Carcinoma in China: A Comparative Analysis of HAIC-FO and Sorafenib. (Pubmed Central) - Jul 21, 2024
Additionally, probabilistic sensitivity analysis indicated a 99.8% probability that the ICER for HAIC-FO compared with sorafenib would fall below the WTP threshold. CONCLUSIONS Compared with sorafenib, HAIC-FO emerged as a cost-effective first-line treatment option for patients facing advanced HCC in China.
- Avastin (bevacizumab) / Roche, ompenaclid (RGX-202) / Inspirna, EMD Serono
A randomized blinded Phase 2 study of ompenaclid (RGX-202-01) vs placebo in combination with FOLFIRI plus bevacizumab (BEV) in patients (pts) with previously treated RAS mutated (RASmt) advanced/metastatic colorectal cancer (mCRC) (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_2489;
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
PRODIGE 86 (FFCD 2103 - GONO) (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_2487;
- ||| M9466 / EMD Serono
New P1 trial, Combination therapy, Metastases: M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) (clinicaltrials.gov) - Jul 18, 2024
P1, N=54, Not yet recruiting, Sponsor: EMD Serono Research & Development Institute, Inc.
- | New P1/2 trial, Metastases: ISMCC: Immunosurveillance for Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 18, 2024
P1/2, N=200, Active, not recruiting, Sponsor: MIPO Clinic
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
PROGNOSTIC VALUE OF THE TP53 MUTATION IN PATIENTS WITH PANCREATIC DUCTAL ADENOCARCINOMA RECEIVING FOLFIRINOX (Poster Stage 4) - Jul 18, 2024 - Abstract #UEGW2024UEGW_3055;
PDAC patients with wild type TP53 demonstrated longer OS than those with TP53 mutation, and this trend was intensified in patients with localized disease. This result may be due to an impaired response to FOLFIRINOX chemotherapy in patients with TP53 mutation.
- 5-fluorouracil / Generic mfg.
THE IMPACT OF COMBINED CHEMOTHERAPY AND INTRA-TUMORAL INJECTION OF PHOSPHORUS-32 MICROPARTICLES ON VASCULARITY IN LOCALLY ADVANCED PANCREATIC CARCINOMA (Poster Stage 3) - Jul 18, 2024 - Abstract #UEGW2024UEGW_3044;
The result of this current study forms a platform to understand further, the potential benefits of chemoradiotherapy over chemotherapy alone in patients with LAPC. Larger comparative trials are warranted.
- USE OF STATINS INCREASES OVERALL SURVIVAL IN PATIENTS AFFECTED BY PANCREATIC DUCTAL ADENOCARCINOMA (Poster Stage 3) - Jul 18, 2024 - Abstract #UEGW2024UEGW_3038;
The present results suggest that chronic use of statins is significantly associated with increased OS in patients affected by PDAC at Cox proportional hazard regression. Whether this beneficial effect is due to less indolent tumours or better response to treatments require further investigation.
- FOLFIRINOX VERSUS GEMCITABINE/NAB-PACLITAXEL IN METASTATIC PANCREATIC CANCER: A REAL-WORLD DATA ANALYSIS INCLUDING NGS PANEL INSIGHTS (Poster Stage 4) - Jul 18, 2024 - Abstract #UEGW2024UEGW_2744;
FOLFIRINOX can be considered 1st-line regimen in metastatic disease. The NGS data suggest RNF43 could be a potential predictive marker for the response to Gemcitabine/Nab-Paclitaxel, however, larger size confirmation study is needed to validate this finding.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
IDENTIFYING DRUGGABLE TUMOR-IMMUNE INTERACTIONS IN ATM-DEFICIENT PANCREATIC CANCER (Poster Stage 4) - Jul 18, 2024 - Abstract #UEGW2024UEGW_2743;
The NGS data suggest RNF43 could be a potential predictive marker for the response to Gemcitabine/Nab-Paclitaxel, however, larger size confirmation study is needed to validate this finding. Through single cell-resolved multiomics analyses of ATM-deficient PDACs, and validation in human cases, we unveil transcriptional, translational, and secretory regulatory events, shed light on the intricate interplay between tumor genetics and PDAC microenvironment, and pave the way for the elaboration of novel personalized therapies.
- 5-fluorouracil / Generic mfg.
IMPACT OF PANCREATIC INSUFFICIENCY AND BASELINE NUTRITIONAL STATUS IMPAIRMENT ON CHEMOTHERAPY DOSE-INTENSITY IN PATIENTS WITH ADVANCED PANCREATIC CANCER (Poster Stage 4) - Jul 18, 2024 - Abstract #UEGW2024UEGW_2742;
P=N/A
Reduction of DI is correlated with markers of impaired nutritional status in patients with advanced PDAC deemed suitable for chemotherapy. Malnutrition treatment and tool-assisted screening may enable more appropriate care and improved results.
- 5-fluorouracil / Generic mfg.
COMBINED 32P IMPLANTATION AND CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE FOR LOCALLY ADVANCED PANCREATIC CANCER: A PROPENSITY-SCORE WEIGHTED LANDMARK ANALYSIS (Poster Stage 4) - Jul 18, 2024 - Abstract #UEGW2024UEGW_2740;
As no direct comparison has been made, our aim was to compare FOLFIRINOX alone and FOLFIRINOX with 32P implantation in a propensity-score weighted analysis... This first comparative study between standard chemotherapy and chemotherapy with additional 32P microparticles implantation has demonstrated significant survival, disease control and downstaging benefits of combination therapy with chemotherapy and 32P microparticle implantation.
- 5-fluorouracil / Generic mfg.
RNA-SEQUENCING ON EUS-ACQUIRED TISSUE OF PANCREATIC CANCER IS FEASIBLE AND ALLOWS IDENTIFICATION OF BIOMARKERS OF PROGNOSIS AND OF RESPONSE TO INTENSIFIED CHEMOTHERAPY (Poster Stage 4) - Jul 18, 2024 - Abstract #UEGW2024UEGW_1734;
This first comparative study between standard chemotherapy and chemotherapy with additional 32P microparticles implantation has demonstrated significant survival, disease control and downstaging benefits of combination therapy with chemotherapy and 32P microparticle implantation. Transcriptome analysis of EUS-FNA samples is feasible and allows stratification of PDAC patients in terms of prognosis and chemosensitivity.Few selected classifiers such as QKI, GATA6 and REG4 may be sufficient to predict response to certain treatments.
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
COMPLETE RADIOLOGICAL DISAPPEARANCE OF RECURRENT HETEROGENEOUS SYNCHRONOUS GASTRIC CANCERS FOLLOWING EFFECTIVE CHEMOTHERAPY WITH IMMUNE CHECKPOINT INHIBITOR: A CASE REPORT (Science Lounge) - Jul 18, 2024 - Abstract #UEGW2024UEGW_824;
This case demonstrates the potential for complete remission in treatment-resistant gastric cancer through a combination of surgery, conventional chemotherapy, and immunotherapy. It highlights the importance of personalized treatment plans based on tumor characteristics such as HER2 status and MSI, contributing to the evolving landscape of gastric cancer management.
- || Clinical, Retrospective data, Journal: Adjuvant Concurrent Chemoradiotherapy (CRT) plus Docetaxel-Cisplatin-Fluorouracil (DCF) versus CRT plus Fluorouracil-Folinic Acid (FUFA) in Stage III Gastric Cancer. (Pubmed Central) - Jul 18, 2024
It highlights the importance of personalized treatment plans based on tumor characteristics such as HER2 status and MSI, contributing to the evolving landscape of gastric cancer management. In conclusion, when compared with FUFA regimen, more aggressive therapy with DCF was more toxic and did not improve OS in adjuvant setting of stage III gastric cancer.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Mucinous intestinal adenocarcinoma arising from mature cystic teratoma of the ovary treated with FOLFOX-6 - a case report. (Pubmed Central) - Jul 18, 2024
This is among the few reports detailing the effective use of the FOLFOX 6 chemotherapy regimen for treating this type of intestinal cancer. Furthermore, we emphasize the immunohistochemical results that confirm the colorectal histological origin.
- | Journal, Metastases: Outcomes of locally advanced gastric and gastroesophageal adenocarcinoma cancers treated with neoadjuvant FLOT in a tertiary care hospital in Pakistan. (Pubmed Central) - Jul 18, 2024
Our findings confirm that FLOT is an effective and well-tolerated perioperative regimen with reasonable response rates in the Pakistani population. A more extensive longitudinal study would ensure these preliminary results in the local patient population.
- | Jelmyto (mitomycin urothelial gel) / UroGen
Trial completion date, Trial primary completion date: PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer (clinicaltrials.gov) - Jul 17, 2024
P1, N=49, Recruiting, Sponsor: City of Hope Medical Center
A more extensive longitudinal study would ensure these preliminary results in the local patient population. Trial completion date: Dec 2025 --> Aug 2026 | Trial primary completion date: Dec 2025 --> Aug 2026
- | Avastin (bevacizumab) / Roche
Journal, Metastases: Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer. (Pubmed Central) - Jul 17, 2024
Trial completion date: Dec 2025 --> Aug 2026 | Trial primary completion date: Dec 2025 --> Aug 2026 Although 2-year mortality could be reasonably estimated, the HTE analysis showed that clinically available variables did not reliably identify which patients with mCRC benefit from FOLFOXIRI versus FOLFOX/FOLFIRI, both plus bevacizumab, across the three studies.
- || methotrexate / Generic mfg.
Clinical, Retrospective data, Review, Journal: Comparing the risk of severe oral mucositis associated with methotrexate as graft-versus host-disease prophylaxis to other immunosuppressive prophylactic agents in hematopoietic cell transplantation: a systematic review and meta-analysis. (Pubmed Central) - Jul 17, 2024
When appropriate, MMF, FA, and a mini-dose of MTX may be an alternative that is associated with less SOM. This work also underlines the scarcity of RCTs on MTX interventions to provide the best evidence-based recommendations.